Sfoglia per Autore
From biology to clinical experience : evolution in the knowledge of neuroendocrine tumours
2009 E. Bajetta, G. Procopio, S. Pusceddu, F. Pietrantonio, M. Milione, M. Maccauro, E. Verzoni, V. Guadalupi, M. Platania
Succinate dehydrogenase B subunit immunohistochemical expression predicts aggressiveness in well differentiated neuroendocrine tumors of the ileum
2012 M. Milione, S. Pusceddu, P. Gasparini, F. Melotti, P. Maisonneuve, V. Mazzaferro, F.G. de Braud, G. Pelosi
Pancreatic well-differentiated neuroendocrine neoplasms (PWDNENS) : What place for everolimus and sunitinib derived from esmo clinical practice guidelines in the therapeutic algorithm?
2013 S. Pusceddu, R. Buzzoni, F. De Braud
Malignant pheochromocytoma and paraganglioma : future considerations for therapy
2013 R. Buzzoni, S. Pusceddu, A. Damato, E. Meroni, C. Aktolun, M. Milione, V. Mazzaferro, F. De Braud, C. Spreafico, M. Maccauro, N. Zaffaroni, M.R. Castellani
Well-differentiated neuroendocrine tumor of tailgut cyst : A rare entity with controversial medical opportunities
2013 A. Damato, S. Pusceddu, M. Milione, V. Mazzaferro, M. Magli, E. Seregni, F. De Braud, R. Buzzoni
Rationale and protocol of the MetNET-1 trial, a prospective, single center, phase II study to evaluate the activity and safety of everolimus in combination with octreotide LAR and metformin in patients with advanced pancreatic neuroendocrine tumors
2014 S. Pusceddu, F. De Braud, L. Concas, C. Bregant, L. Leuzzi, B. Formisano, R. Buzzoni
Safety profile and treatment response of everolimus in different solid tumors : an observational study
2014 E. Verzoni, S. Pusceddu, R. Buzzoni, E. Garanzini, A. Damato, P. Biondani, I. Testa, P. Grassi, E. Bajetta, F. Debraud, G. Procopio
Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy : a phase II ITMO study
2014 R. Buzzoni, S. Pusceddu, E. Bajetta, F. De Braud, M. Platania, C. Iannacone, M. Cantore, A. Mambrini, A. Bertolini, O. Alabiso, A. Ciarlo, C. Turco, V. Mazzaferro
Fatal case of hepatic portal venous gas following palliative stenting and chemotherapy for occlusive advanced colorectal cancer
2015 M. Platania, B. Valeri, A. Marchianò, G. Calareso, F. Agustoni, E. Haspinger, S. Pusceddu, M.C. Garassino, F. Gelsomino, F. de Braud
Erratum: Real-world study of everolimus in advanced progressive neuroendocrine tumors (The Oncologist, (2014) 19, (966-974), 10.1634/theoncologist.2014-0037)
2015 F. Panzuto, M. Rinzivillo, N. Fazio, F. de Braud, G. Luppi, M.C. Zatelli, F. Lugli, P. Tomassetti, F. Riccardi, C. Nuzzo, M.P. Brizzi, A. Faggiano, A. Zaniboni, E. Nobili, D. Pastorelli, S. Cascinu, M. Merlano, S. Chiara, L. Antonuzzo, C. Funaioli, F. Spada, S. Pusceddu, A. Fontana, M.R. Ambrosio, A. Cassano, D. Campana, G. Cartenì, M. Appetecchia, A. Berruti, A. Colao, M. Falconi, G. Delle Fave
Evolution in the treatment of gastroenteropancreatic-neuroendocrine neoplasms, focus on systemic therapeutic options : a systematic review
2015 S. Pusceddu, F. De Braud, F. Festinese, C. Bregant, A. Lorenzoni, M. Maccauro, M. Milione, L. Concas, B. Formisano, L. Leuzzi, V. Mazzaferro, R. Buzzoni
Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors
2016 G. Lo Russo, S. Pusceddu, N. Prinzi, M. Imbimbo, C. Proto, D. Signorelli, M. Vitali, M. Ganzinelli, M. Maccauro, R. Buzzoni, E. Seregni, F. de Braud, M.C. Garassino
How do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studies
2016 S. Pusceddu, F. De Braud, G. Lo Russo, L. Concas, D. Femia, C. Vernieri, A. Indini, B. Formisano, R. Buzzoni
Diagnosis and management of typical and atypical lung carcinoids
2016 S. Pusceddu, G. Lo Russo, M. Macerelli, C. Proto, M. Vitali, D. Signorelli, M. Ganzinelli, P. Scanagatta, L. Duranti, A. Trama, R. Buzzoni, G. Pelosi, U. Pastorino, F. de Braud, M.C. Garassino
Metformin with everolimus and octreotide in pancreatic neuroendocrine tumor patients with diabetes
2016 S. Pusceddu, R. Buzzoni, C. Vernieri, L. Concas, S. Marceglia, L. Giacomelli, M. Milione, L. Leuzzi, D. Femia, B. Formisano, V. Mazzaferro, F. De Braud
Treatment of lung large cell neuroendocrine carcinoma
2016 G. Lo Russo, S. Pusceddu, C. Proto, M. Macerelli, D. Signorelli, M. Vitali, M. Ganzinelli, R. Gallucci, N. Zilembo, M. Platania, R. Buzzoni, F. de Braud, M.C. Garassino
Primary Cerebellar Neuroendocrine Tumors: Chimeras or Real Entities? A Case Report with a 6-Year Follow-Up
2016 C. Vernieri, D. Femia, S. Pusceddu, C. Capella, J. Rosai, G. Calareso, L. Concas, N. Prinzi, G. Lo Russo, F. De Braud, R. Buzzoni
Update on medical treatment of small intestinal neuroendocrine tumors
2016 S. Pusceddu, D. Femia, G. Lo Russo, S. Ortolani, M. Milione, M. Maccauro, C. Vernieri, N. Prinzi, L. Concas, L. Leuzzi, F. De Braud, R. Buzzoni
Primary tumour resection may improve survival in functional well-differentiated neuroendocrine tumours metastatic to the liver
2017 D. Citterio, S. Pusceddu, A. Facciorusso, J. Coppa, M. Milione, R. Buzzoni, M. Bongini, F. Debraud, V. Mazzaferro
The underestimated role of somatostatin analogs in the NETTER-1 trial
2017 S. Pusceddu, R. Buzzoni, F. De Braud
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile